Nykode Therapeutics AS (Euronext Growth Oslo: NYKD)

https://www.nykode.com

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases. Nykode’s modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses. Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive interim efficacy and safety results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group. Additionally, Nykode is conducting a Phase 1/2 trial with next-generation COVID-19 vaccine candidates. The Company’s partnerships include Genentech within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development. Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). *

	Start	2021-11-30 renamed
	Predecessor	Vaccibody AS (Euronext Growth Oslo: VACC)
	Industry	vaccine technology
	Industry 2	cancer vaccine
	Person	Engsig, Michael (Vaccibody 202010 CEO)
	Person 2	Bonde, Martin (Vaccibody 201508– CEO before EpiTherapeutics ApS + Aros Pharma ApS + Natimmune AS + Combio AS)

	Region	Oslo
	Country	Norway
	Street	21 Gaustadalléen Oslo Science Park
	City	0349 Oslo
	Tel	+47-22-958193
		Address record changed: 2022-12-22

Basic data	Employees	n. a.

		* Document for »About Section«: Nykode Therapeutics A/S. (12/19/22). "Press Release: Nykode Therapeutics and Richter-Helm BioLogics Announce Strategic Manufacturing Partnership". Oslo.

		Record changed: 2024-02-12